NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth

Shannon T. Bailey, Penelope L. Miron, Yoon J. Choi, Bose Kochupurakkal, Gautam Maulik, Scott J. Rodig, Ruiyang Tian, Kathleen M. Foley, Teresa V. Bowman, Alexander Miron, Myles Brown, J. Dirk Iglehart, Debajit K. Biswas

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Breast cancers with HER2 overexpression are sensitive to drugs targeting the receptor or its kinase activity. HER2-targeting drugs are initially effective against HER2-positive breast cancer, but resistance inevitably occurs. We previously found that NF-κB is hyperactivated in a subset of HER2-positive breast cancer cells and tissue specimens. In this study, we report that constitutively active NF-κB rendered HER2-positive cancer cells resistant to anti-HER2 drugs and cells selected for lapatinib resistance upregulated NF-κB. In both circumstances, cells were antiapoptotic and grew rapidly as xenografts. Lapatinib-resistant cells were refractory to HER2 and NF-κB inhibitors alone but were sensitive to their combination, suggesting a novel therapeutic strategy. A subset of NF-κB-responsive genes was overexpressed in HER2-positive and triple-negative breast cancers, and patients with this NF-κB signature had poor clinical outcome. Anti-HER2 drug resistance may be a consequence of NF-κB activation, and selection for resistance results in NF-κB activation, suggesting that this transcription factor is central to oncogenesis and drug resistance. Clinically, the combined targeting of HER2 and NF-κB suggests a potential treatment paradigm for patients who relapse after anti-HER2 therapy. Patients with these cancers may be treated by simultaneously suppressing HER2 signaling and NF-κB activation. Implications: The combination of an inhibitor of Ik B kinase (IKK) inhibitor and anti-HER2 drugs may be a novel treatment strategy for drug-resistant human breast cancers.

Original languageEnglish (US)
Pages (from-to)408-420
Number of pages13
JournalMolecular Cancer Research
Volume12
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Apoptosis
Breast Neoplasms
Growth
Pharmaceutical Preparations
Drug Delivery Systems
Neoplasms
Drug Resistance
Phosphotransferases
Triple Negative Breast Neoplasms
Drug Receptors
Therapeutics
Heterografts
Carcinogenesis
Transcription Factors
Recurrence
Genes
lapatinib

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Bailey, S. T., Miron, P. L., Choi, Y. J., Kochupurakkal, B., Maulik, G., Rodig, S. J., ... Biswas, D. K. (2014). NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth. Molecular Cancer Research, 12(3), 408-420. https://doi.org/10.1158/1541-7786.MCR-13-0206-T

NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth. / Bailey, Shannon T.; Miron, Penelope L.; Choi, Yoon J.; Kochupurakkal, Bose; Maulik, Gautam; Rodig, Scott J.; Tian, Ruiyang; Foley, Kathleen M.; Bowman, Teresa V.; Miron, Alexander; Brown, Myles; Iglehart, J. Dirk; Biswas, Debajit K.

In: Molecular Cancer Research, Vol. 12, No. 3, 2014, p. 408-420.

Research output: Contribution to journalArticle

Bailey, ST, Miron, PL, Choi, YJ, Kochupurakkal, B, Maulik, G, Rodig, SJ, Tian, R, Foley, KM, Bowman, TV, Miron, A, Brown, M, Iglehart, JD & Biswas, DK 2014, 'NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth', Molecular Cancer Research, vol. 12, no. 3, pp. 408-420. https://doi.org/10.1158/1541-7786.MCR-13-0206-T
Bailey, Shannon T. ; Miron, Penelope L. ; Choi, Yoon J. ; Kochupurakkal, Bose ; Maulik, Gautam ; Rodig, Scott J. ; Tian, Ruiyang ; Foley, Kathleen M. ; Bowman, Teresa V. ; Miron, Alexander ; Brown, Myles ; Iglehart, J. Dirk ; Biswas, Debajit K. / NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth. In: Molecular Cancer Research. 2014 ; Vol. 12, No. 3. pp. 408-420.
@article{bee9272a222243a68a9813e0d2fbd547,
title = "NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth",
abstract = "Breast cancers with HER2 overexpression are sensitive to drugs targeting the receptor or its kinase activity. HER2-targeting drugs are initially effective against HER2-positive breast cancer, but resistance inevitably occurs. We previously found that NF-κB is hyperactivated in a subset of HER2-positive breast cancer cells and tissue specimens. In this study, we report that constitutively active NF-κB rendered HER2-positive cancer cells resistant to anti-HER2 drugs and cells selected for lapatinib resistance upregulated NF-κB. In both circumstances, cells were antiapoptotic and grew rapidly as xenografts. Lapatinib-resistant cells were refractory to HER2 and NF-κB inhibitors alone but were sensitive to their combination, suggesting a novel therapeutic strategy. A subset of NF-κB-responsive genes was overexpressed in HER2-positive and triple-negative breast cancers, and patients with this NF-κB signature had poor clinical outcome. Anti-HER2 drug resistance may be a consequence of NF-κB activation, and selection for resistance results in NF-κB activation, suggesting that this transcription factor is central to oncogenesis and drug resistance. Clinically, the combined targeting of HER2 and NF-κB suggests a potential treatment paradigm for patients who relapse after anti-HER2 therapy. Patients with these cancers may be treated by simultaneously suppressing HER2 signaling and NF-κB activation. Implications: The combination of an inhibitor of Ik B kinase (IKK) inhibitor and anti-HER2 drugs may be a novel treatment strategy for drug-resistant human breast cancers.",
author = "Bailey, {Shannon T.} and Miron, {Penelope L.} and Choi, {Yoon J.} and Bose Kochupurakkal and Gautam Maulik and Rodig, {Scott J.} and Ruiyang Tian and Foley, {Kathleen M.} and Bowman, {Teresa V.} and Alexander Miron and Myles Brown and Iglehart, {J. Dirk} and Biswas, {Debajit K.}",
year = "2014",
doi = "10.1158/1541-7786.MCR-13-0206-T",
language = "English (US)",
volume = "12",
pages = "408--420",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth

AU - Bailey, Shannon T.

AU - Miron, Penelope L.

AU - Choi, Yoon J.

AU - Kochupurakkal, Bose

AU - Maulik, Gautam

AU - Rodig, Scott J.

AU - Tian, Ruiyang

AU - Foley, Kathleen M.

AU - Bowman, Teresa V.

AU - Miron, Alexander

AU - Brown, Myles

AU - Iglehart, J. Dirk

AU - Biswas, Debajit K.

PY - 2014

Y1 - 2014

N2 - Breast cancers with HER2 overexpression are sensitive to drugs targeting the receptor or its kinase activity. HER2-targeting drugs are initially effective against HER2-positive breast cancer, but resistance inevitably occurs. We previously found that NF-κB is hyperactivated in a subset of HER2-positive breast cancer cells and tissue specimens. In this study, we report that constitutively active NF-κB rendered HER2-positive cancer cells resistant to anti-HER2 drugs and cells selected for lapatinib resistance upregulated NF-κB. In both circumstances, cells were antiapoptotic and grew rapidly as xenografts. Lapatinib-resistant cells were refractory to HER2 and NF-κB inhibitors alone but were sensitive to their combination, suggesting a novel therapeutic strategy. A subset of NF-κB-responsive genes was overexpressed in HER2-positive and triple-negative breast cancers, and patients with this NF-κB signature had poor clinical outcome. Anti-HER2 drug resistance may be a consequence of NF-κB activation, and selection for resistance results in NF-κB activation, suggesting that this transcription factor is central to oncogenesis and drug resistance. Clinically, the combined targeting of HER2 and NF-κB suggests a potential treatment paradigm for patients who relapse after anti-HER2 therapy. Patients with these cancers may be treated by simultaneously suppressing HER2 signaling and NF-κB activation. Implications: The combination of an inhibitor of Ik B kinase (IKK) inhibitor and anti-HER2 drugs may be a novel treatment strategy for drug-resistant human breast cancers.

AB - Breast cancers with HER2 overexpression are sensitive to drugs targeting the receptor or its kinase activity. HER2-targeting drugs are initially effective against HER2-positive breast cancer, but resistance inevitably occurs. We previously found that NF-κB is hyperactivated in a subset of HER2-positive breast cancer cells and tissue specimens. In this study, we report that constitutively active NF-κB rendered HER2-positive cancer cells resistant to anti-HER2 drugs and cells selected for lapatinib resistance upregulated NF-κB. In both circumstances, cells were antiapoptotic and grew rapidly as xenografts. Lapatinib-resistant cells were refractory to HER2 and NF-κB inhibitors alone but were sensitive to their combination, suggesting a novel therapeutic strategy. A subset of NF-κB-responsive genes was overexpressed in HER2-positive and triple-negative breast cancers, and patients with this NF-κB signature had poor clinical outcome. Anti-HER2 drug resistance may be a consequence of NF-κB activation, and selection for resistance results in NF-κB activation, suggesting that this transcription factor is central to oncogenesis and drug resistance. Clinically, the combined targeting of HER2 and NF-κB suggests a potential treatment paradigm for patients who relapse after anti-HER2 therapy. Patients with these cancers may be treated by simultaneously suppressing HER2 signaling and NF-κB activation. Implications: The combination of an inhibitor of Ik B kinase (IKK) inhibitor and anti-HER2 drugs may be a novel treatment strategy for drug-resistant human breast cancers.

UR - http://www.scopus.com/inward/record.url?scp=84897049249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897049249&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-13-0206-T

DO - 10.1158/1541-7786.MCR-13-0206-T

M3 - Article

VL - 12

SP - 408

EP - 420

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 3

ER -